MDT shares respect the 200‑day moving average and have formed a bullish ascending channel, with RSI near 58 indicating upside potential. Fundamentals remain solid with 2025 earnings beat, strong cash flow and UBS’s new $110 target implying 15‑20% upside from current levels.

Investor sentiment is overwhelmingly positive, reflected by multiple buy recommendations and a surge in analyst coverage after UBS raised its price target. The stock is riding the broader healthcare rally and AI‑driven medtech optimism, keeping momentum strong.

Key risks include potential regulatory headwinds and global reimbursement pressure, but Medtronic’s diversified product mix and pipeline mitigate long‑term downside. Earnings growth is expected to stay in the mid‑single‑digit range over the next 12‑18 months, supporting a sustainable bullish outlook.

The daily MACD crossed above its signal line and volume surged to 1.6× the 20‑day average, while the 10‑day EMA stayed above the 30‑day EMA, generating a bullish technical signal. Quant models project a 4‑6% price appreciation over the next 30 days, aligning with the $110 target.